Car-T Cell Therapy Market, By Targeted Antigen (CD 19, CD 20, GD 2, CD 22, CD 30, CD 33, HER1, HER2, MESO, EGFRVIII AND Others); By Application (Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Non Hodgkin Leukemia, Multiple Myeloma, Pancreatic Cancer, Neuroblasta, Breast Cancer, Acute Myeloid Leukemia, Hepatocellular Carcinoma, Colorectal Cancer And Others) – Global Industry Insights, Trends And Forecast – 2017 To 2025

Created On: Jul-2018
Report ID: IR123
Format: PDF

Car-T Cell Therapy Market: Introduction

Car-T cell therapy is a type of treatment in which, the T cells (taken from blood) of a patient are modified so that they can fight cancer cells. It improves the body’s ability to detect and kill cancer cells.  Primarily, in this cancer treatment T-cells will accumulate, modified with CAR protein and is injected into the patient’s body. These cells then will act as an attacker on the cancer cells. This treatment is widely being adopted to treat various type of cancer includes pancreas cancer, colorectal cancer, breast cancer, and blood cancer.  The car-T cell therapy market size is anticipated to grow significantly over the projected period, owing to the growing cancer patients across the globe coupled with the approval of new therapies to cure the cancer.

Market Dynamics

The market is majorly driven by the rising incidence of numerous types of cancers including breast cancer, Leukemia, and others. For instance, in 2018, World Health Organization has estimated breast cancer cases recorded was 2.09 million cases, across the globe which would frost the global CAR-T cell therapy market share in the coming decade.  Furthermore, the incidence of Leukemia (acute Lymphocytic Leukemia) is rising, due to which  the U.S Food and Drug Administration has approved two Car-T cell therapies- Kymriah and Yescrata, used for the treatment of Leukemia which further accelerate the car-T cell therapy market.  Additionally, with the rising government initiatives in the healthcare industries and promoting research in cell therapy will accelerate the market growth. For instance, in 2016, the National Cancer Advisory Board has funded US$ 1.8 Bn, to foster the research process, to make more therapies available to patients with cancer.

However, various side effects are associated with the car-t cell therapy such as severe headaches, confusion, neurotoxity, and others. Moreover, it can also lead to cytokine release syndrome (CRS) and other neurological problems such as coma, hallucinations, and delirium, act as a restraining factor for the Car-T Cell Therapy market size growth.

Targeted Antigen Insights

CD 19 targeted antigen is anticipated to grow substantially over the CAGR over the forecast period owing to the rising clinical applications on the pronounced trial of the targeted CD19. This successful trial was funded by Kite Pharma for the treatment of B-cell lymphoma is further fueling the growth of Car-T cell therapy market share. The key pharmaceutical companies Kite Pharma, Novartis AG, Collectes S.A. and, others are involved in the manufacturing of CD 19 targeted antigen.

Application Insights

Leukemia disease particularly acute lymphocytic leukemia, chronic lymphocytic leukemia, and acute myeloid leukemia are perceived to grow at the significant CAGR over the forecast period followed by breast cancer. The growth is attributable due to the rising incidences of leukemia coupled with the increasing clinical trials to treat leukemia. For instance, in 2017, a clinical trial was initiated for the treatment of acute myeloid leukemia by using the combination of 8 different drugs including PF-04518600, avelumab, and azacitidine, glasdegib and avelumab and others. The trial is expected to accomplish by December 2024, which will further boost the Car-T Cell Therapy market size growth.

Regional Insights

North America is anticipated to dominate the Car-T Cell Therapy market share owing to the enhancement of new therapies for cancer treatment. For instance, in 2017, the U.S. Food and Drug Administration (FDA) has approved Kymriah, a therapy to treat pediatric and young adult patients, who are diagnosed with acute lymphoblastic leukemia. This new therapy will further accelerate the market trend over the forecast year. Moreover, the growing cases of diseases in America such as breast cancer, Acute Lymphocytic Leukemia, and others will further foster the market growth. For instance, according to American Cancer Society, approximately 5,960 new incidences and 1,470 deaths by acute lymphocytic leukemia has been recorded, that further increases the opportunity for the Car-T cell therapy in US market.

Europe is expected to have significant growth over the forecast period, largely owing to the rising research and development on car-t cell therapies in the European region. For instance, in 2017, European Hematology and Oncology conducted a study on car-t cell therapy for Leukapheresis in the patients. This type of studies would increase the awareness amongst the population. Therefore, it would propel the Car-T Cell Therapy market size growth. .

Competitive Landscape

The key players operating in the market includes Celgene Corporation, Bellicum Pharmaceuticals, Pfizer, Inc. Kite Pharma, Inc., and several others. To stay competitive in the market, the players are involved in new product enhancement, and mergers & acquisitions. For instance, in 2018, Celgene Corporation, a developer of of Car-T and TCR (T cell receptor) announced to acquire June Therapeutics, Inc. to develop the transformative medicine for patients diagnosed with blood cancer. Moreover, strategic alliances are taking place to stay competitive in the global CAR-T cell therapy market. For instance, in April 2018, Pfizer, Inc. signed a deal with Allogene, for the development of an investigational CAR-T cell therapy for treating various types of blood cancer.

Our Research Approach Includes
  •  Market Outlining
  •  Framing discussion guide
  •  Data Validation
  • Data Analysis
  •  Re-Validation and Finalization of Data
  •  Report Insights and Publishing
Our Research Approach Includes
  •  Market Outlining
  •  Framing discussion guide
  •  Data Validation
  • Data Analysis
  •  Re-Validation and Finalization of Data
  •  Report Insights and Publishing
Reach Out to us